News Search Results
Mar 18, 2025, 16:05 ET INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
MEETING, Pa., March 18, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Mar 18, 2025, 16:00 ET Oracle and NVIDIA Collaborate to Help Enterprises Accelerate Agentic AI Inference
or at the edge. This offering provides an integrated AI stack to help address data privacy, sovereign AI, and low-latency requirements. Biotechnology company Soley Therapeutics is deploying OCI AI infrastructure, NVIDIA AI Enterprise, and NVIDIA Blackwell GPUs to build its AI drug discovery platform
More news about: Oracle
Mar 18, 2025, 12:13 ET Insecticides Market To Reach USD 12.4 Billion By 2030, Growing At A 4.80% CAGR - Credence Research
https://www.credenceresearch.com/report/crop-protection-chemicals-market Agriculture Biotechnology Market - https://www.credenceresearch.com/report/agriculture-biotechnology-market Follow Us:
More news about: Credence Research Inc.
Mar 18, 2025, 10:01 ET Central Lab Services Market worth US$8.18 billion by 2030with 6.5% CAGR | MarketsandMarkets™
ICON plc (Ireland): ICON plc offers outsourced drug development services to the pharmaceutical, biotechnology, and medical device industries. The company provides clinical, consulting, and commercial services ranging from trial design to post-market commercialization.
More news about: MarketsandMarkets
Mar 18, 2025, 09:00 ET Ninth Annual "Feeding the Economy" Report Demonstrates Immense Impact of the American Food and Agriculture Industry Amidst Economic Challenges
Frozen Food InstituteAmerican Peanut CouncilAmerican Soybean AssociationAssociation of Equipment ManufacturersBiotechnology Innovation OrganizationConsumer Brands AssociationCorn Refiners AssociationCropLife AmericaEdible Oil Producers
More news about: Food and Agriculture Industry Organizations
Mar 18, 2025, 08:03 ET TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead
March 18, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced initiatives to outsource several
More news about: TC BioPharm
Mar 18, 2025, 08:00 ET Japanese-Founded Regulatory T-cell Reprogramming Company RegCell Secures $45.8M in Funding and Completes U.S. Headquarters Transition
EMERYVILLE, Calif., March 18, 2025 /PRNewswire/ -- RegCell, Inc., a biotechnology company developing first-in-class therapies for autoimmune diseases and transplantation with its epigenetic reprogramming platform leveraging the
More news about: RegCell, Inc.
Mar 18, 2025, 08:00 ET Tecsys Expands Global Reach with Roche's Adoption of Elite™ for Laboratory Inventory Management
Tecsys Inc. (TSX: TCS), a global leader in supply chain management solutions, announced that Roche, the world's largest biotechnology company and global leader in in-vitro diagnostics, has selected Tecsys' Elite™ platform for implementation across Roche's network of core laboratory
More news about: Tecsys Inc.
Mar 18, 2025, 08:00 ET Tecsys Expands Global Reach with Roche's Adoption of Elite™ for Laboratory Inventory Management
Tecsys Inc. (TSX: TCS), a global leader in supply chain management solutions, announced that Roche, the world's largest biotechnology company and global leader in in-vitro diagnostics, has selected Tecsys' Elite™ platform for implementation across Roche's network of core laboratory
More news about: Tecsys Inc.
Mar 18, 2025, 07:30 ET Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes
March 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it has started enrolling patients into
More news about: Virax Biolabs
Mar 18, 2025, 05:45 ET ICON Public Limited Company Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 11, 2025 to Discuss Your Rights - ICLR
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Levi & Korsinsky, LLP
Mar 18, 2025, 04:00 ET Cipla and Formosa sign multi-regional licensing deal for Clobetasol Suspension
throughout its term. About Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. (6838.TW) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®),
More news about: Formosa Pharmaceuticals Inc.,
Mar 17, 2025, 18:00 ET TaiMed Biologics Announces Results from Late-Breaking Phase 2a Data on Long-Acting HIV Maintenance Therapy at CROI 2025
[email protected]. About TaiMed Biologics Founded in 2007, TaiMed Biologics (4147.TWO) is a leading commercial-stage biotechnology company focused on developing innovative therapies for HIV treatment. The company successfully launched ibalizumab (Trogarzo®), the world's first
More news about: TaiMed Biologics
Mar 17, 2025, 18:00 ET TaiMed Biologics Announces Results from Late-Breaking Phase 2a Data on Long-Acting HIV Maintenance Therapy at CROI 2025
[email protected]. About TaiMed Biologics Founded in 2007, TaiMed Biologics (4147.TWO) is a leading commercial-stage biotechnology company focused on developing innovative therapies for HIV treatment. The company successfully launched ibalizumab (Trogarzo®), the world's first
More news about: TaiMed Biologics
Mar 17, 2025, 17:31 ET VITRAKVI Maintains Market Leadership Across the 7MM Amid Growing TRK Inhibitor Competition | DelveInsight
namely, DOVBLERON (taletrectinib/AB-106/IBI-344) (Nuvation Bio/Innovent Biologics/Daiichi Sankyo/Nippon Kayaku) and ANS03 (Avistone Biotechnology), being evaluated for NSCLC. Taletrectinib (AB-106/IBI-344) is a next-generation, selective ROS1 inhibitor designed for treating advanced
More news about: DelveInsight Business Research, LLP
Mar 17, 2025, 13:00 ET BioCentriq Rebrands as Made Scientific to Redefine Cell Therapy, Defy Limits, and Deliver Results
the global expertise and resources of GC Corporation of South Korea, a global leader in the pharmaceutical and biotechnology sectors. For More Information Contact [email protected]
More news about: Made Scientific, Inc
Mar 17, 2025, 12:12 ET City of Miami Mayor Francis Suarez and JP Global Advisors Founder Jeannette Paulino Host Exclusive Fireside Chat at Anthony Ritossa's 24th Global Family Office Investment Summit
Mayor Suarez explored Miami's five-year vision, which prioritizes safety, low taxes and innovation with the convergence of finance, technology, and biotechnology among the key drivers of economic expansion. Under Mayor Suarez's tenure, the city has attracted companies managing over $12 trillion in assets,
More news about: Ritossa Family Office
Mar 17, 2025, 12:00 ET Micro Bioreactor System Market Booms at 10.7% CAGR - Innovations in Pharma & Biotech Drive Growth | Valuates Reports
this market are Sartorius, Applikon Biotechnology, Pall Corporation, PARR, M2p-labs, INFORS HT and others. The top 5 companies share a market share of about 50% in 2019. Key Companies: SartoriusApplikon BiotechnologyEppendorfPall CorporationParrM2p-labsPBS
More news about: Valuates Reports
Mar 17, 2025, 10:13 ET Theradaptive Welcomes Jeffrey W. Dunn to its Board of Directors
Mr. Dunn brings over three decades of leadership experience in the medical device, biotechnology, and technology sectors. Currently serving as Chairman of the Board at SI-BONE, Inc., a leading musculoskeletal medical device company he co-founded
More news about: Theradaptive
Mar 17, 2025, 09:00 ET Gene Bio Medical and BIDIPHAR Announce Strategic Joint Venture to Revolutionize Global Healthcare
Vietnam, March 17, 2025 /PRNewswire/ - Gene Bio Medical (GBM), a leading Canadian biotechnology company specializing in molecular diagnostics, has signed a Memorandum of Understanding (MOU) with Bình Định Pharmaceutical - Medical Equipment
More news about: Gene Bio Medical
Mar 17, 2025, 09:00 ET Evommune Initiates Phase 2 Trial of IL-18 Targeted Fusion Protein, EVO301, in Adult Patients with Atopic Dermatitis
Calif., March 17, 2025 /PRNewswire/ -- Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the enrollment of the first patient
More news about: Evommune, Inc
Mar 17, 2025, 08:00 ET Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and Chief Executive Officer, Dr. Amit
More news about: Anixa Biosciences, Inc.
Mar 17, 2025, 08:00 ET Arthrosi Announces First Patient Dosed in Replicate Pivotal Phase 3 REDUCE 1 Trial of Lead Compound AR882
DIEGO, March 17, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels,
More news about: Arthrosi Therapeutics
Mar 17, 2025, 07:45 ET ChromaTan and Landmark Bio Awarded National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) Grant to Advance Intensified Recombinant Adeno-Associated Virus (AAV) Production Process
About ChromaTan, Inc.Headquartered in Spring House, PA, ChromaTan is a trusted partner to the biotechnology industry, specializing in biomanufacturing process intensification through its proprietary Biologic Real Moving Bed (BioRMB™) technology. BioRMB™
More news about: Landmark Bio
Mar 17, 2025, 07:00 ET Tract Bio Announces Publication in Gastroenterology Revealing Potential Therapeutic Targets in the Evolution of Esophageal Adenocarcinoma Identified Using stemECHO™ Cloning Platform
BOSTON, March 17, 2025 /PRNewswire/ -- Tract Bio, a biotechnology company discovering and developing novel therapies for cancer and inflammatory disease, today announced the publication of preclinical research
More news about: Tract Bio